Metronomic oral low-dose treosulfan chemotherapy combined with cyclooxygenase-2 inhibitor in pretreated advanced melanoma: A pilot study

Cancer Chemotherapy and Pharmacology

Volumn 52, Issue 5, 2003, Pages 377-382

  Spieth, Konstanze ^a   Kaufmann, Roland ^a   Gille, Jens ^a  

^a UNIVERSITY HOSPITAL FRANKFURT   (Germany)

Author keywords

Antineoplastic combined chemotherapy protocol; Clinical trial; Melanoma

Indexed keywords

ANALGESIC AGENT; ANTIEMETIC AGENT; CYCLOOXYGENASE 2 INHIBITOR; HISTAMINE H3 RECEPTOR ANTAGONIST; METOCLOPRAMIDE; N (2 CYCLOHEXYLOXY 4 NITROPHENYL)METHANESULFONAMIDE; ROFECOXIB; TRAMADOL; TREOSULFAN;

ADULT; AGED; ALOPECIA; ANGIOGENESIS; APOPTOSIS; ARTICLE; BLOOD TOXICITY; CANCER COMBINATION CHEMOTHERAPY; CANCER STAGING; CELL FUNCTION; CELL PROLIFERATION; CLINICAL ARTICLE; CLINICAL TRIAL; CONSTIPATION; CONTROLLED CLINICAL TRIAL; CONTROLLED STUDY; CYTOTOXICITY; DIARRHEA; DISEASE ACTIVITY; DOSE RESPONSE; DRUG EFFICACY; DRUG SAFETY; DRUG TARGETING; ENDOTHELIUM CELL; ENZYME INHIBITION; FATIGUE; FEMALE; FEVER; GASTROINTESTINAL TOXICITY; HUMAN; HUMAN CELL; LOW DRUG DOSE; MALE; MELANOMA; METASTASIS; NAUSEA; PAIN; PILOT STUDY; PRIORITY JOURNAL; QUALITY OF LIFE; SURVIVAL TIME; VOMITING; WEIGHT REDUCTION;

ADULT; AGED; ANTINEOPLASTIC AGENTS, ALKYLATING; APOPTOSIS; BUSULFAN; CELL DIVISION; CELL SURVIVAL; CELLS, CULTURED; CYCLOOXYGENASE 2; CYCLOOXYGENASE 2 INHIBITORS; CYCLOOXYGENASE INHIBITORS; DISEASE PROGRESSION; DRUG THERAPY, COMBINATION; ENDOTHELIAL CELLS; FEMALE; HUMANS; ISOENZYMES; LACTONES; MALE; MELANOMA; MEMBRANE PROTEINS; MIDDLE AGED; PILOT PROJECTS; PROSTAGLANDIN-ENDOPEROXIDE SYNTHASES; SULFONES;

EID: 0242329662     PISSN: 03445704     EISSN: None     Source Type: Journal    
DOI: 10.1007/s00280-003-0678-9     Document Type: Article

References (20)

1. Bajetta E, Del Vecchio M, Bernard-Marty C, Vitali M, Buzzoni R, Rixe O, Nova P, Aglione S, Taillibert S, Khayat D (2002) Metastatic melanoma: chemotherapy. Semin Oncol 29:427
2. Bello L, Carrabba G, Giussani C, Lucini V, Cerutti F, Scaglione F, Landre J, Pluderi M, Tomei G, Villani R, Carroll RS, Black PM, Bikfalvi A (2001) Low-dose chemotherapy combined with an antiangiogenic drug reduces human glioma growth in vivo. Cancer Res 61:7501
3. Bocci G, Nicolaou KC, Kerbel RS (2002) Protracted low-dose effects on human endothelial cell proliferation and survival in vitro reveal a selective antiangiogenic window for various chemotherapeutic drugs. Cancer Res 62:6938
4. Browder T, Butterfield CE, Kraling BM, Shi B, Marshall B, O'Reilly MS, Folkman J (2000) Antiangiogenic scheduling of chemotherapy improves efficacy against experimental drug-resistant cancer. Cancer Res 60:1878
5. Chapman PB, Einhorn LH, Meyers ML, Saxman S, Destro AN, Panageas KS, Begg CB, Agarwala SS, Schuchter LM, Ernstoff MS, Houghton AN, Kirkwood JM (1999) Phase III multicenter randomized trial of the Dartmouth regimen versus dacarbazine in patients with metastatic melanoma. J Clin Oncol 17:2745
6. Falkson CI, Ibrahim J, Kirkwood JM, Coates AS, Atkins MB, Blum RH (1998) Phase III trial of dacarbazine versus dacarbazine with interferon alpha-2b versus dacarbazine with tamoxifen versus dacarbazine with interferon alpha-2b and tamoxifen in patients with metastatic malignant melanoma: an Eastern Cooperative Oncology Group study. J Clin Oncol 16:1743
7. Hilger RA, Jacek G, Oberhoff C, Kredtke S, Baumgart J, Seeber S, Scheulen ME (2000) Investigation of bioavailability and pharmacokinetics of treosulfan capsules in patients with relapsed ovarian cancer. Cancer Chemother Pharmacol 45:483
8. Huncharek M, Caubet JF, McGarry R (2001) Single-agent DTIC versus combination chemotherapy with or without immunotherapy in metastatic melanoma: a meta-analysis of 3273 patients from 20 randomized trials. Melanoma Res 11:75
9. Keldsen N, Madsen EL, Havsteen H, Kamby C, Laursen L, Sandberg E (1998) Oral treosulfan as second-line treatment in platinum-resistant ovarian cancer: a phase II study. The Danish Ovarian Cancer Study Group. Gynecol Oncol 69:100
10. Kerbel RS, Klement G, Pritchard KI, Kamen B (2002) Continuous low-dose anti-angiogenic/metronomic chemotherapy: from the research laboratory into the oncology clinic. Ann Oncol 13:12
11. Klement G, Baruchel S, Rak J, Man S, Clark K, Hicklin DJ, Bohlen P, Kerbel RS (2000) Continuous low-dose therapy with vinblastine and VEGF receptor-2 antibody induces sustained tumor regression without overt toxicity. J Clin Invest 105:R15
12. Meden H, Wittkop Y, Kuhn W (1997) Maintenance chemotherapy with oral treosulfan following first-line treatment in patients with advanced ovarian cancer: feasibility and toxicity. Anticancer Res 17:2221
13. Miller KD, Sweeney CJ, Sledge GW Jr (2001) Redefining the target: chemotherapeutics as antiangiogenics. J Clin Oncol 19:1195
14. Morton DL, Essner D, Kirkwood JM, Wollman RC (2000) Malignant melanoma. In: Bast RC, Kufe DW, Pollock RE, Weichselbaum RR, Holland JF, Frei E, (eds) Cancer medicine, 5th edn. BC Decker, Hamilton, Ontario, pp 1849-1869
15. Neuber K, tom DA, Blodorn-Schlicht N, Itschert G, Karnbach C (1999) Treosulfan is an effective alkylating cytostatic for malignant melanoma in vitro and in vivo. Melanoma Res 9:125
16. Neuber K, Reinhold U, Deutschmann A, Pfohler C, Mohr P, Pichlmeier U, Baumgart J, Hauschild A (2003) Second-line chemotherapy of metastatic malignant melanoma with intravenous treosulfan: a phase II multicenter trial. Melanoma Res 13:81
17. Onn A, Tseng JE, Herbst RS (2001) Thalidomide, cyclooxygenase-2, and angiogenesis: potential for therapy. Clin Cancer Res 7:3311
18. Scappaticci FA (2002) Mechanisms and future directions for angiogenesis-based cancer therapies. J Clin Oncol 20:3906
19. Tsujii M, Kawano S, Tsuji S, Sawaoka H, Hori M, DuBois RN (1998) Cyclooxygenase regulates angiogenesis induced by colon cancer cells. Cell 93:705
20. Vacca A, Iurlaro M, Ribatti D, Minischetti M, Nico B, Ria R, Pellegrino A, Dammacco F (1999) Antiangiogenesis is produced by nontoxic doses of vinblastine. Blood 94:4143